Visible Genomics Launches DNA Age-Related Macular Degeneration Testing

Visible Genomics, a Chicago-area genetics testing company, has announced the launch of a new noninvasive genetic eye test that the company says determines a patient’s likelihood of contracting age-related macular degeneration (AMD).

While it’s estimated that up to 70% of AMD cases are due to genetics, its prevalence is increasing with the aging population, which puts an additional 20 million people with a family history of the disease at risk. The new Visible Genomics test is recommended for people who have a family history of the disease, or those showing signs of early or intermediate AMD, which are the highest group risks for progressing to advanced stages of AMD with vision loss.                              

Visible Genomics created the genetic assessment test specifically for AMD to help doctors and their patients take preventative and proactive care of their vision. The clinically-validated saliva-based test combines a person’s genetic status, ocular findings, and demographic and lifestyle characteristics to deliver a comprehensive and clinically actionable risk assessment, according to a company news release. This assessment determines the AMD patient’s progression risk of developing advanced AMD, and predicts the lifetime risk for those with a family member with AMD.                                                      

“Age-related macular degeneration is one of the leading causes of blindness in the United States, yet there’s a lack of accessible and reliable genetic risk testing options that can help with proper diagnosis and prognosis,” Visible Genomics CEO and Founder Frank Adamo said in the news release. “Our healthcare system is reactive instead of proactive and preventative. With use of the Visible Genomics testing system, we can now give doctors and their patients the right tools to help prevent vision loss.”

For more information visit Visible Genomics.